Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Launched by FRENCH INNOVATIVE LEUKEMIA ORGANISATION · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying older patients, aged 60 and over, who have been diagnosed with a type of blood cancer called acute myeloid leukemia (AML). The goal is to understand the characteristics of these patients and how they respond to a specific type of treatment known as intensive induction therapy, which aims to achieve complete remission (meaning no signs of cancer). The trial will help researchers learn more about how age and other factors affect treatment outcomes, especially since the incidence of AML increases with age.

To participate in this trial, patients must be 60 years or older, have not received treatment for AML before, and be deemed suitable for intensive therapy. Patients will be asked to read an information document and provide consent for their data to be collected. The study is currently recruiting participants, and while it offers hope for better understanding and treatment of AML in older individuals, it is essential to note that not everyone will be eligible—those with certain health issues or conditions will be excluded. This research is crucial for improving the care and outcomes for older patients with AML.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 60 and over
• • Patients with previously untreated de novo or secondary AML
• • Patients suitable for standard intensive treatment
• • Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent).
• Exclusion Criteria:
• • Patients with AML 3
• • Patients with severe, uncontrolled infection at the time of inclusion
• • Patients with psychiatric or social disorders that will prevent compliance with the protocol
• • Patients without health insurance (affiliation to a social security scheme)

Trial Officials